Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial
We report the first durability data from a head-to-head study of an optimized self-replicating RNA vaccine for rabies that elicits sustained immune responses compared to a commercial comparator that uses a traditional vaccine technology.
Authors
- Nathaniel Wang (ORCID: https://orcid.org/0000-0002-6396-7644)
- Parinaz Aliahmad (ORCID: https://orcid.org/0000-0002-2655-2829)
- Guillermo Somodevilla
- Jessica L. Sparks (ORCID: https://orcid.org/0000-0002-7800-6029)
- Shigeki J. Miyake‐Stoner (ORCID: https://orcid.org/0000-0002-4867-0666)
- Zelanna Goldberg
- Andrew J. Geall (ORCID: https://orcid.org/0000-0003-3138-9218)
- C. Maine
- Brandon Essink (ORCID: https://orcid.org/0000-0002-7309-228X)
- Gaelle Picarda
Institutions
- Bioscience Research (US)
- Velocity Clinical Research (United States) (US)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1038/s43856-025-01147-4
- Citations
- 1
- Primary Topic
- Rabies epidemiology and control
- Type
- article
- Field-Weighted Citation Impact
- 1.04